The efficacy and acceptability of pharmacological monotherapies and e-cigarette on smoking cessation: a systemic review and network meta-analysis
Frontiers in Public Health · 22.05.2024 · 12
DOI: 10.3389/fpubh.2024.1361186 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Public Health, online erschienen am 22.05.2024. Verfasst von Yajing Meng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Mental Health Center, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Smoking Cessation, Electronic Nicotine Delivery Systems, Varenicline, Tobacco Use Cessation Devices. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aims Several pharmacological interventions, such as nicotine replacement therapy (NRT), varenicline, and bupropion, have been approved for clinical use of smoking cessation. E-cigarettes (EC) are increasingly explored by many RCTs for their potentiality in smoking cessation. In addition, some RCTs are attempting to explore new drugs for smoking cessation, such as cytisine. This network meta-analysis (NMA) aims to investigate how these drugs and e-cigarettes compare regarding their efficacy and acceptability. Materials and methods This systematic review and NMA searched all clinical studies on smoking cessation using pharmacological monotherapies or e-cigarettes published from January 2011 to May 2022 using MEDLINE, COCHRANE Library, and PsychINFO databases. NRTs were divided into transdermal (TDN) and oronasal nicotine (ONN) by administrative routes, thus 7 network nodes were set up for direct and indirect comparison. Two different indicators measured the efficacy: prevalent and continuous smoking abstinence. The drop-out rates measured the acceptability.
Results
The final 40 clinical studies included in this study comprised 77 study cohorts and 25,889 participants. Varenicline is more effective intervention to assist in smoking cessation during 16–32 weeks follow-up, and is very likely to prompt dropout. Cytisine shows more effectiveness in continuous smoking cessation but may also lead to dropout. E-cigarettes and oronasal nicotine are more effective than no treatment in encouraging prevalent abstinence, but least likely to prompt dropout. Finally, transdermal nicotine delivery is more effective than no treatment in continuous abstinence, with neither significant effect on prevalent abstinence nor dropout rate.
Conclusion
This review suggested and agreed that Varenicline, Cytisine and transdermal nicotine delivery, as smoking cessation intervention, have advantages and disadvantages. However, we had to have reservations about e-cigarettes as a way to quit smoking in adolescents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mental Health Center, West China Hospital of Sichuan University, Chengdu, China.
- Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD, United States.
- Department of Cardiology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
Zitieren
APA
Meng, Y., Xiang, S., Qu, L., & Li, Y. (2024). The efficacy and acceptability of pharmacological monotherapies and e-cigarette on smoking cessation: a systemic review and network meta-analysis. Frontiers in Public Health, 12. https://doi.org/10.3389/fpubh.2024.1361186
Vancouver
Meng Y, Xiang S, Qu L, Li Y. The efficacy and acceptability of pharmacological monotherapies and e-cigarette on smoking cessation: a systemic review and network meta-analysis. Frontiers in Public Health. 2024;12. doi:10.3389/fpubh.2024.1361186
BibTeX
@article{Meng2024,
author = {Meng, Yajing and Xiang, Sike and Qu, Lang and Li, Ying},
title = {The efficacy and acceptability of pharmacological monotherapies and e-cigarette on smoking cessation: a systemic review and network meta-analysis},
journal = {Frontiers in Public Health},
year = {2024},
volume = {12},
doi = {10.3389/fpubh.2024.1361186}
}
EUVIMED